Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Phase 1 Completed
167 enrolled
Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer
Phase 1 Completed
6 enrolled
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1 Completed
62 enrolled 17 charts
Raltitrexed in HIPEC
Phase 1 Completed
30 enrolled
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
Phase 1 Completed
52 enrolled
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
Phase 1 Completed
101 enrolled
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Phase 1 Completed
67 enrolled
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
Phase 1 Completed
39 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Phase 1 Completed
42 enrolled
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
34 enrolled
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Phase 1 Completed
27 enrolled
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
Phase 1 Completed
10 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
AMPLIFY-201
Phase 1 Completed
25 enrolled 15 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1 Completed
185 enrolled 28 charts
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
Phase 1 Completed
54 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Phase 1 Completed
46 enrolled
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
Phase 1 Completed
11 enrolled
A Study of CDX-585 in Patients With Advanced Malignancies
Phase 1 Completed
20 enrolled
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Phase 1 Completed
17 enrolled
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
Phase 1 Completed
46 enrolled
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Phase 1 Completed
43 enrolled
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Phase 1 Completed
86 enrolled
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Phase 1 Completed
89 enrolled
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
13 enrolled
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Phase 1 Completed
38 enrolled
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Phase 1 Completed
64 enrolled
MGD019 DART® Protein in Unresectable/Metastatic Cancer
Phase 1 Completed
162 enrolled
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Phase 1 Completed
9 enrolled
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Phase 1 Completed
40 enrolled
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Phase 1 Completed
37 enrolled
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Phase 1 Completed
9 enrolled
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
Phase 1 Completed
24 enrolled
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
48 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
KEYNOTE-651
Phase 1 Completed
116 enrolled 18 charts
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
Study of Intermittent OSI-906 Dosing
Phase 1 Completed
79 enrolled
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase 1 Completed
95 enrolled
IVY
Phase 1 Completed
353 enrolled